Literature DB >> 25225343

Reply to "compliance with antimicrobial therapy for buruli ulcer".

Richard O Phillips1, Fred S Sarfo2, Mohammed K Abass3, Michael Frimpong4, Edwin Ampadu5, Mark Forson6, Yaw A Amoako2, William Thompson3, Kingsley Asiedu7, Mark Wansbrough-Jones8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25225343      PMCID： PMC4187934          DOI： 10.1128/AAC.03874-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  9 in total

1.  Opportunities for the elimination of tuberculosis.

Authors:  J O Mason
Journal:  Am Rev Respir Dis       Date:  1986-08

2.  Compliance with antimicrobial therapy for buruli ulcer.

Authors:  S Klis; R Kingma; W Tuah; Y Stienstra; T S van der Werf
Journal:  Antimicrob Agents Chemother       Date:  2014-10       Impact factor: 5.191

3.  Effectiveness of excision of pre-ulcerative Buruli lesions in field situations in a rural district in Ghana.

Authors:  G Amofah; S Asamoah; C Afram-Gyening
Journal:  Trop Doct       Date:  1998-04       Impact factor: 0.731

4.  A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine.

Authors:  W D Revill; R H Morrow; M C Pike; J Ateng
Journal:  Lancet       Date:  1973-10-20       Impact factor: 79.321

5.  Patient compliance: the most serious remaining problem in the control of tuberculosis in the United States.

Authors:  W W Addington
Journal:  Chest       Date:  1979-12       Impact factor: 9.410

6.  Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease.

Authors:  Fred Stephen Sarfo; Richard Phillips; Kingsley Asiedu; Edwin Ampadu; Nana Bobi; E Adentwe; Awuli Lartey; Ishmael Tetteh; M Wansbrough-Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-06-21       Impact factor: 5.191

7.  Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.

Authors:  Willemien A Nienhuis; Ymkje Stienstra; William A Thompson; Peter C Awuah; K Mohammed Abass; Wilson Tuah; Nana Yaa Awua-Boateng; Edwin O Ampadu; Vera Siegmund; Jan P Schouten; Ohene Adjei; Gisela Bretzel; Tjip S van der Werf
Journal:  Lancet       Date:  2010-02-03       Impact factor: 79.321

8.  Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease).

Authors:  Annick Chauty; Marie-Françoise Ardant; Ambroise Adeye; Hélène Euverte; Augustin Guédénon; Christian Johnson; Jacques Aubry; Eric Nuermberger; Jacques Grosset
Journal:  Antimicrob Agents Chemother       Date:  2007-05-25       Impact factor: 5.191

9.  Buruli ulcer recurrence, Benin.

Authors:  Martine Debacker; Julia Aguiar; Christian Steunou; Claude Zinsou; Wayne M Meyers; Françoise Portaels
Journal:  Emerg Infect Dis       Date:  2005-04       Impact factor: 6.883
  9 in total
  2 in total

1.  Barriers to Buruli ulcer treatment completion in the Ashanti and Central Regions, Ghana.

Authors:  Shelui Collinson; Venus N B Frimpong; Bernadette Agbavor; Bethany Montgomery; Michael Oppong; Michael Frimpong; Yaw A Amoako; Michael Marks; Richard O Phillips
Journal:  PLoS Negl Trop Dis       Date:  2020-05-26

Review 2.  Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease).

Authors:  Rie R Yotsu; Marty Richardson; Norihisa Ishii
Journal:  Cochrane Database Syst Rev       Date:  2018-08-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.